View highlights and coverage from leading international congresses
It was a pleasure to speak to Deepak Jadon (Cambridge University Hospitals, Cambridge, UK) about his research highlights from this year in the field of psoriatic arthritis (PsA) and his highlights from the annual ACR Convergence meeting. Questions What have been the most notable research articles published in PsA this year? (0:05) What were the […]
Following his presentation at ACR 2020, we spoke with Richard Furie (Northwell Health Zucker School of Medicine at Hofstra/Northwell, NY, USA) about the novel IL-2 conjugate, NKTR-358 in patients with systemic lupus erythematosus (Clinical Trial Identifier: NCT03556007). The abstract ‘Selective Expansion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus by a Novel IL-2 […]
It was a pleasure to speak with Marina Magrey (Case Western Reserve University School of Medicine/ MetroHeath Medical Center, Cleveland, OH, USA) about the recent post-hoc analysis from the COAST X study (NCT02757352). The analysis was designed to evaluate the efficacy of ixekizumab at week 16 in patients with non-radiographic axial spondyloarthritis (nr-axSpA) with or […]
TouchIMMUNOLOGY was delighted to speak with Marina Magrey (Case Western Reserve University School of Medicine/ MetroHeath Medical Center, Cleveland, OH, USA) about non-radiographic axial spondyloarthritis (nr-axSpA), its prognosis and the unmet needs in its treatment. Disclosures: Marina Magrey has served as a consultant for Novartis, Eli Lilly, Pfizer, AbbVie, UCB and Janssen. She has also […]
We were delighted to speak to Ihsane Hmamouchi regarding the use of clomipramine for the treatment of chronic lumbar radicular pain. The abstract ‘Efficacy of Clomipramine for Chronic Lumbar Radicular Pain a Randomized Clinical Trial’ (ABSTRACT NUMBER: 0962) was presented at the virtual ACR Convergence 2020, 5-9 November 2020. Questions What is the rationale for […]
We caught up with Roy Fleischmann (Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, TX, USA) to discuss the use of sarilumab in patients with rheumatoid arthritis (Clinical Trial Identifier: NCT01146652). The abstract ‘Long-term Safety and Efficacy of Sarilumab over 5 Years in Patients with Rheumatoid Arthritis Refractory to Tumor Necrosis Factor […]
Walter Maksymowych (University of Alberta, Alberta, Canada) talks to touchIMMUNOLOGY about the results of the C-axSpAnd Study (NCT02552212). This 52-week placebo-controlled study aimed to identify demographic or baseline characteristics of patients with nr-axSpA that could be predictive of achieving a clinical response to treatment with certolizumab pegol. The abstract entitled ‘Predictors of Response in Patients […]
In Part 2, Thomas MacDonald (University of Dundee, Dundee, Scotland, UK) discusses further how the results of the FAST study compared to another study, the CARES trial, which also investigated the cardiovascular risks associated with these two treatments. The late-breaking abstract entitled ‘Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: […]
Following concerns related to the cardiovascular safety of febuxostat, the European Medicines Agency recommended a post-licensing study assessing the cardiovascular safety of febuxostat compared with allopurinol. Here we talk to Thomas MacDonald (University of Dundee, Dundee, Scotland, UK) about the results of this study and what they mean. The late-breaking abstract entitled ‘Long Term Cardiovascular […]
Get the latest clinical insights from touchIMMUNOLOGY
